Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
Portfolio Pulse from
Aadi Bioscience has appointed David Dornan, PhD, as its new Chief Scientific Officer. Dornan brings extensive expertise in antibody-drug conjugates (ADC) to support the company's pipeline.
February 18, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aadi Bioscience has appointed David Dornan, PhD, as Chief Scientific Officer, bringing significant expertise in antibody-drug conjugates to the company.
The appointment of a seasoned leader with expertise in ADCs is likely to positively impact Aadi Bioscience's strategic direction and pipeline development, potentially leading to increased investor confidence.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100